SAN DIEGO, March 9, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from three in vitro dissolution studies exploring the dissolution performance of INGREZZA® (valbenazine) capsule contents through soft foods or a gastrostomy (G-tube) feeding tube. The data (Poster #IND03, Valbenazine Capsule Contents for Potential Administration via Soft Food/Feeding Tube) will be presented at AMDA – The Society for Post-Acute and Long-Term Care Medicine's PALTC23 Annual Conference being held March 9-12 in Tampa, Florida.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.